FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602445194> ?p ?o ?g. }

• W2602445194 endingPage "4191" @default.
• W2602445194 startingPage "4181" @default.
• W2602445194 abstract "The purpose of this article was two-fold: first, to optimize a recently proposed two-stage single-compartment in vitro test for the evaluation of dissolution in the lower intestine with the mini-paddle apparatus in the fasted and fed state using two model high dose, low solubility drugs [sulfasalazine (Azulfidine) and micronized aprepitant] and one mesalamine colon targeting product (Asacol, 400 mg/tablet); second, to evaluate the impact of passive absorption from the lower intestine on the overall absorption process using three model high dose, low solubility drugs [micronized aprepitant, SB705498, and albendazole (Zentel)]. The intensity of agitation and the physicochemical characteristics of fluids simulating the environment in the distal ileum and the proximal colon were optimized and the importance of solid particles was evaluated. Dissolution data collected under conditions simulating the upper and lower intestine were coupled with physiologically based oral absorption modeling to simulate the average plasma levels or the average absorption process. Reliability of the modeling approach was evaluated based on previously collected data in adults. The impact of solid particles on dissolution in the lower intestine was found to be clinically insignificant for Asacol tablets, as well as for sulfasalazine (Azulfidine) and micronized aprepitant. Average plasma levels (micronized aprepitant and SB705498) and cumulative amount absorbed (albendazole) could be adequately simulated by referring only to events in the upper gastrointestinal lumen, indicating that the impact of absorption from the lower intestine on actual plasma levels was minimal. Dissolution of Asacol tablets and immediate release formulations in the lower intestine can be adequately evaluated by employing Level II biorelevant media. However, simulation of actual drug particle dissolution in the lower intestine is not typically necessary for adequate prediction of oral absorption from immediate release formulations containing discrete, dispersed particles of lipophilic drugs." @default.
• W2602445194 created "2017-04-07" @default.
• W2602445194 creator A5015685483 @default.
• W2602445194 creator A5042680980 @default.
• W2602445194 creator A5059985546 @default.
• W2602445194 creator A5072939921 @default.
• W2602445194 creator A5081839906 @default.
• W2602445194 date "2017-04-13" @default.
• W2602445194 modified "2023-10-17" @default.
• W2602445194 title "Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs" @default.
• W2602445194 cites W1457247235 @default.
• W2602445194 cites W1529123505 @default.
• W2602445194 cites W1581897560 @default.
• W2602445194 cites W1593169456 @default.
• W2602445194 cites W1937237220 @default.
• W2602445194 cites W1966923209 @default.
• W2602445194 cites W1970120001 @default.
• W2602445194 cites W1977584199 @default.
• W2602445194 cites W1986611047 @default.
• W2602445194 cites W1992556111 @default.
• W2602445194 cites W1996190454 @default.
• W2602445194 cites W2005249562 @default.
• W2602445194 cites W2009537932 @default.
• W2602445194 cites W2009697466 @default.
• W2602445194 cites W20344856 @default.
• W2602445194 cites W2046677990 @default.
• W2602445194 cites W2054031365 @default.
• W2602445194 cites W2057327484 @default.
• W2602445194 cites W2060318369 @default.
• W2602445194 cites W2063928570 @default.
• W2602445194 cites W2073430961 @default.
• W2602445194 cites W2075737449 @default.
• W2602445194 cites W2079306905 @default.
• W2602445194 cites W2093493395 @default.
• W2602445194 cites W2124744988 @default.
• W2602445194 cites W2323969994 @default.
• W2602445194 cites W2355987922 @default.
• W2602445194 cites W2465210897 @default.
• W2602445194 cites W2516987210 @default.
• W2602445194 cites W252369352 @default.
• W2602445194 cites W275104397 @default.
• W2602445194 doi "https://doi.org/10.1021/acs.molpharmaceut.6b01129" @default.
• W2602445194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28366005" @default.
• W2602445194 hasPublicationYear "2017" @default.
• W2602445194 type Work @default.
• W2602445194 sameAs 2602445194 @default.
• W2602445194 citedByCount "24" @default.
• W2602445194 countsByYear W26024451942017 @default.
• W2602445194 countsByYear W26024451942018 @default.
• W2602445194 countsByYear W26024451942019 @default.
• W2602445194 countsByYear W26024451942020 @default.
• W2602445194 countsByYear W26024451942021 @default.
• W2602445194 countsByYear W26024451942022 @default.
• W2602445194 countsByYear W26024451942023 @default.
• W2602445194 crossrefType "journal-article" @default.
• W2602445194 hasAuthorship W2602445194A5015685483 @default.
• W2602445194 hasAuthorship W2602445194A5042680980 @default.
• W2602445194 hasAuthorship W2602445194A5059985546 @default.
• W2602445194 hasAuthorship W2602445194A5072939921 @default.
• W2602445194 hasAuthorship W2602445194A5081839906 @default.
• W2602445194 hasConcept C112705442 @default.
• W2602445194 hasConcept C125287762 @default.
• W2602445194 hasConcept C126322002 @default.
• W2602445194 hasConcept C147789679 @default.
• W2602445194 hasConcept C155574463 @default.
• W2602445194 hasConcept C159985019 @default.
• W2602445194 hasConcept C178790620 @default.
• W2602445194 hasConcept C181389837 @default.
• W2602445194 hasConcept C185592680 @default.
• W2602445194 hasConcept C192562407 @default.
• W2602445194 hasConcept C2776694085 @default.
• W2602445194 hasConcept C2777226302 @default.
• W2602445194 hasConcept C2777882243 @default.
• W2602445194 hasConcept C2780574406 @default.
• W2602445194 hasConcept C2780884295 @default.
• W2602445194 hasConcept C55493867 @default.
• W2602445194 hasConcept C71924100 @default.
• W2602445194 hasConcept C88380143 @default.
• W2602445194 hasConcept C98274493 @default.
• W2602445194 hasConceptScore W2602445194C112705442 @default.
• W2602445194 hasConceptScore W2602445194C125287762 @default.
• W2602445194 hasConceptScore W2602445194C126322002 @default.
• W2602445194 hasConceptScore W2602445194C147789679 @default.
• W2602445194 hasConceptScore W2602445194C155574463 @default.
• W2602445194 hasConceptScore W2602445194C159985019 @default.
• W2602445194 hasConceptScore W2602445194C178790620 @default.
• W2602445194 hasConceptScore W2602445194C181389837 @default.
• W2602445194 hasConceptScore W2602445194C185592680 @default.
• W2602445194 hasConceptScore W2602445194C192562407 @default.
• W2602445194 hasConceptScore W2602445194C2776694085 @default.
• W2602445194 hasConceptScore W2602445194C2777226302 @default.
• W2602445194 hasConceptScore W2602445194C2777882243 @default.
• W2602445194 hasConceptScore W2602445194C2780574406 @default.
• W2602445194 hasConceptScore W2602445194C2780884295 @default.
• W2602445194 hasConceptScore W2602445194C55493867 @default.
• W2602445194 hasConceptScore W2602445194C71924100 @default.
• W2602445194 hasConceptScore W2602445194C88380143 @default.
• W2602445194 hasConceptScore W2602445194C98274493 @default.

• next